m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05654
 [1]
m6A modification lncRNA4114 lncRNA4114 METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA lncRNA4114 Regulated Target  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Long intergenic non-protein coding RNA 1638 (LINC01638)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Long intergenic non-protein coding RNA 1638 (LINC01638) LncRNA View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Overexpression of methyltransferase like 3 (METTL3) promoted the osteogenic differentiation of PPDLSCs, while knocking down METTL3 showed an inhibitory effect. Furthermore, METTL3 overexpression promotes the stability of Long intergenic non-protein coding RNA 1638 (LINC01638) to upregulate the expression level. Moreover, lncRNA4114 overexpression promoted the osteogenic differentiation of PPDLSCs.
Responsed Disease Periodontitis ICD-11: DA0C
 Disease Info 
Cell Process Cell differentiation
In-vitro Model
 PPDLSCs (Porcine Periodontal Ligament Stem Cells)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
DA0C: Periodontitis 7 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name AlloDerm Approved [2]
Synonyms
AlloCraft; Cymetra; GraftJacket; Repliform; Strattice; Graft tissue product, LifeCell
    Click to Show/Hide
External Link
TTD: D0EW5Y
 Compound Name Trafermin Phase 3 [3]
Synonyms
Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN)
    Click to Show/Hide
External Link
TTD: D0KV1Q
 Compound Name RhGDF-5 Phase 2 [4]
Synonyms
MD-05; MD-06; MD-07; MD-08; RhGDF-5 (bone regeneration); MP52 (BCP carrier, bone regeneration), BioPharm/Scil; RhGDF-5 (bone regeneration), Scil/Medtronic; RhGDF-5 (implantable bone substitute), BioPharm/Scil; MP52 (beta-tricalciumphosphate carrier, bone regeneration), BioPharm/Scil
    Click to Show/Hide
External Link
TTD: D0V4IQ
 Compound Name PerioPatch Phase 2 [5]
External Link
TTD: D0U8IU
 Compound Name MSI-469 Terminated [6]
External Link
TTD: D0H4GE
 Compound Name Sharon-3000 Investigative [7]
External Link
TTD: D0E4TD
 Compound Name BT-301 Investigative [7]
Synonyms
PRF-K
    Click to Show/Hide
External Link
TTD: D03WTE
References
Ref 1 N6-methyladenosine promotes osteogenic differentiation of PDLSCs from periodontitis patients. Oral Dis. 2024 Apr;30(3):1322-1336. doi: 10.1111/odi.14467. Epub 2023 Jan 13.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 3 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. doi: 10.1517/14728214.11.4.709.
Ref 4 ClinicalTrials.gov (NCT01124006) A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration. U.S. National Institutes of Health.
Ref 5 Clinical pipeline report, company report or official report of Izun Pharmaceuticals Corp.
Ref 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006076)
Ref 7 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.